Microbial Dysbiosis in Colorectal Cancer (CRC) Patients

By I. Sobhani, Julien Tap, F. Roudot-thoraval, J. Roperch, S. Letulle, P. Langella, G. Corthier, J. T. van Nhieu, J. Furet. PLoS ONE, 2011

802 citations recorded by the source corpus.

The composition of the human intestinal microbiota is linked to health status. The aim was to analyze the microbiota of normal and colon cancer patients in order to establish cancer-related dysbiosis. Patients and Methods Stool bacterial DNA was extracted prior to colonoscopy from 179 patients: 60 with colorectal cancer, and 119 with normal colonoscopy. Bacterial genes obtained by pyrosequencing of 12 stool samples (6 Normal and 6 Cancer) were subjected to a validated Principal Component Analysis (PCA) test. The dominant and subdominant bacterial population (C. leptum, C. coccoides, Bacteroides/Prevotella, Lactobacillus/Leuconostoc/Pediococcus groups, Bifidobacterium genus, and E. coli, and Faecalibacterium prausnitzii species) were quantified in all individuals using qPCR and specific IL17 producer cells in the intestinal mucosa were characterized using immunohistochemistry. Findings Pyrosequencing (Minimal sequence 200 nucleotide reads) revealed 80% of all sequences could be assigned to a total of 819 taxa based on default parameter of Classifier software. The phylogenetic core in Cancer individuals was different from that in Normal individuals according to the PCA analysis, with trends towards differences in the dominant and subdominant families of bacteria. Consequently, All-bacteria [log10 (bacteria/g of stool)] in Normal, and Cancer individuals were similar [11.88±0.35, and 11.80±0.56, respectively, (P = 0.16)], according to qPCR values whereas among all dominant and subdominant species only those of Bacteroides/Prevotella were higher (All bacteria-specific bacterium; P = 0.009) in Cancer (-1.04±0.55) than in Normal (-1.40±0.83) individuals. IL17 immunoreactive cells were significantly expressed more in the normal mucosa of cancer patients than in those with normal colonoscopy. Conclusion This is the first large series to demonstrate a composition change in the microbiota of colon cancer patients with possible impact on mucosal immune response. These data open new filed for mass screening and pathophysiology investigations.

Subfields: Food Science, Infectious Diseases, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/be68ce87cfd369fd69579e8ede6cb5181793bc24

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Food Science

In Infectious Diseases

In Molecular Biology

Citations in the corpus

Current understanding of dysbiosis in disease in human and animal models (2016, result): “Significant differences were seen in both mucosal and fecal microbial compositions between patients in CRC with polyps and those with tumors, with the most significant change being Enterobacteriaceae, which was increased in the mucosa of patients in CRC with tumors compared with those patients with ”
Human Intestinal Lumen and Mucosa-Associated Microbiota in Patients with Colorectal Cancer (2012, background): “An increase of Prevotella was reported in CRC patients [6].”
Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics (2017, background): “F. prausnitzii load Several studies have reported F. prausnitzii depletion in adult CD (Martinez-Medina et al., 2006; Frank et al., 2007; Sokol et al., 2008b, 2009; Swidsinski et al., 2008; Willing et al., 2009; Fujimoto et al., 2013; Miquel et al., 2013), UC (Swidsinski et al., 2005; Sokol et al., ”
Stool Microbiome and Metabolome Differences between Colorectal Cancer Patients and Healthy Adults (2013, background): “[10] found that the Bacteroides/Prevotella group was over-represented in both stool and mucosa samples from individuals with colon cancer compared to their cancer-free counterparts.”
Faecalibacterium prausnitzii and human intestinal health. (2013, background): “prausnitzii has also been analyzed in other diseases such as self limited colitis [22], atopic diseases [37], chronic idiopathic diarrhea [38], acute appendicitis [39], neuroendocrine tumors of the midgut [26], liver transplantation [40] and colorectal cancer (CRC) [41].”
Role of the Microbiota in Immunity and inflammation (2014, background): “Analysis of the microbiome of patients suffering RA revealed a surprising relationship between the disease and a potentially inflammatory clade of Prevotellaceae, but how the microbiota contribute to immune activation and dissemination of T cells and antibodies to the joints in RA is unknown (Scher ”
Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack (2015, background): “Fusobacteria are often enriched in patients with intestinal inflammation and cancer (Sobhani et al., 2011; Strauss et al., 2011).”
Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases (2012, methodology): “Design Faecal and serum BA rates, expressed as a proportion of total BA, were assessed by highperformance liquid chromatography tandem mass spectrometry in colonic IBD patients (42) and healthy subjects (29).”
Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers (2011, background): “…PCR (qPCR) assays, fecal amounts of Desulfovibrio sp. (Scanlan et al., 2009) and Enterococcus faecalis (Balamurugan et al., 2008) were found to be significantly higher in CRC patients than in healthy controls, while Bacteroides/ Prevotella levels were significantly lower (Sobhani et al., 2011).”